SWK Holdings Corp 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39184 SWK Holdings Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 77-0435679 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 14755 Preston Road , Suite 105 Dallas , TX 75254 (Address of Principal Executive Offices) (Zip Code) (Registrant’s Telephone Number, Including Area Code): (972) 687-7250 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share SWKH The Nasdaq Stock Market LLC Preferred Stock Purchase Rights SWKH The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes o No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x Yes o NO Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act: Large Accelerated Filer o Accelerated Filer o Non-Accelerated Filer x Smaller Reporting Company x Emerging Growth Company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o YES x No As of August 3, 2022, there were 12,828,704 shares of the registrant’s Common Stock, $0.001 par value per share, outstanding. SWK Holdings Corporation Form 10-Q Quarter Ended June 30, 2022 Table of Contents PART I. FINANCIAL INFORMATION Item 1. Financial Statements 1 Unaudited Condensed Consolidated Balance Sheets—June 30, 2022 and December 31, 2021 1 Unaudited Condensed Consolidated Statements of Income —Three and Six Months Ended June 30, 2022 and 2021 2 Unaudited Condensed Consolidated Statements of Stockholders’ Equity—Three and Six Months Ended June 30, 2022 and 2021 3 Unaudited Condensed Consolidated Statements of Cash Flows—Six Months Ended June 30, 2022 and 2021 4 Notes to the Unaudited Condensed Consolidated Financial Statements 5 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3. Quantitative and Qualitative Disclosures About Market Risk 26 Item 4 Controls and Procedures 26 PART II. OTHER INFORMATION Item 1. Legal Proceedings 27 Item 1A. Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27 Item 3. Defaults Upon Senior Securities 27 Item 4. Mine Safety Disclosures 27 Item 5. Other Information 27 Item 6. Exhibits 28 Signatures 29 FORWARD-LOOKING STATEMENTS In addition to historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. From time to time, we may also provide oral or written forward-looking statements in other materials we release to the public. Such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. The forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections about our business and industry, and our beliefs and assumptions, and include, but are not limited to, statements under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Words such as “anticipate,” “believe,” “estimate,” “expects,” “intend,” “plan,” “will” and variations of these words and similar expressions identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are beyond our control, are difficult to predict and could cause actual results to differ materially (both favorably and unfavorably) from those expressed or forecasted in the forward-looking statements. These risks and uncertainties include, but are not limited to, those described in Part II, Item 1A, “Risk Factors,” and elsewhere in this report. Forward-looking statements that were believed to be true at the time made may ultimately prove to be incorrect or false. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. PART I. FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS SWK HOLDINGS CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par value and share data) June 30, 2022 December 31, 2021 ASSETS Current assets: Cash and cash equivalents $ 55,118 $ 42,863 Interest and accounts receivable, net 1,869 1,803 Marketable investments 487 1,034 Other current assets 1,366 1,727 Total current assets 58,840 47,427 Finance receivables, net 174,859 181,553 Marketable investments 98 119 Cost method investment 3,491 3,491 Deferred tax assets, net 19,281 20,539 Warrant assets 2,481 3,419 Intangible assets, net 9,042 9,964 Goodwill 8,404 8,404 Property and equipment, net 6,071 5,779 Other non-current assets 1,858 1,970 Total assets $ 284,425 $ 282,665 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable and accrued liabilities $ 2,776 $ 5,087 Revolving credit facility — 8 Total current liabilities 2,776 5,095 Contingent consideration payable 8,530 8,530 Other non-current liabilities 1,589 1,804 Total liabilities 12,895 15,429 Commitments and contingencies (Note 6) Stockholders’ equity: Preferred stock, $ 0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively — — Common stock, $ 0.001 par value; 250,000,000 shares authorized; 12,839,118 and 12,836,133 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively 13 13 Additional paid-in capital 4,431,970 4,431,719 Accumulated deficit ( 4,160,453 ) ( 4,164,496 ) Total stockholders’ equity 271,530 267,236 Total liabilities and stockholders’ equity $ 284,425 $ 282,665 See accompanying notes to the unaudited condensed consolidated financial statements. 1 SWK HOLDINGS CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Revenues: Finance receivable interest income, including fees $ 6,828 $ 11,805 $ 17,243 $ 20,484 Pharmaceutical development 114 10,461 350 10,659 Other — — 480 496 Total revenues 6,942 22,266 18,073 31,639 Costs and expenses: Interest expense 80 94 160 239 Pharmaceutical manufacturing, research and development expense 1,480 1,542 3,381 3,090 Change in fair value of acquisition-related contingent consideration — ( 147 ) — ( 147 ) Depreciation and amortization expense 626 811 1,330 2,493 General and administrative 3,018 3,360 6,178 6,245 Income from operations 1,738 16,606 7,024 19,719 Other (expense) income, net Unrealized net (loss) gain on derivatives ( 472 ) 609 ( 1,165 ) 892 Unrealized net (loss) gain on equity securities ( 519 ) 283 ( 547 ) 1,215 Income before income tax expense 747 17,498 5,312 21,826 Income tax expense 182 3,528 1,269 4,467 Net income $ 565 $ 13,970 $ 4,043 $ 17,359 Net income per share Basic $ 0.04 $ 1.09 $ 0.32 $ 1.36 Diluted $ 0.04 $ 1.09 $ 0.31 $ 1.35 Weighted average shares outstanding Basic 12,835 12,796 12,833 12,794 Diluted 12,885 12,834 12,882 12,822 See accompanying notes to the unaudited condensed consolidated financial statements. 2 SWK HOLDINGS CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (in thousands, except share data) Six Months Ended June 30, 2022 Total Common Stock Additional Accumulated Stockholders’ Shares Amount Paid-In Capital Deficit Equity Balances at December 31, 2021 12,836,133 13 $ 4,431,719 $ ( 4,164,496 ) $ 267,236 Stock-based compensation — — 85 — 85 Issuance of common stock upon vesting of restricted stock 5,495 — — — — Forfeiture of unvested restricted stock ( 6,815 ) — — — — Net income — — — 3,478 3,478 Balances at March 31, 2022 12,834,813 13 4,431,804 ( 4,161,018 ) 270,799 Stock-based compensation — — 166 — 166 Issuance of common stock upon vesting of restricted stock 4,305 — — — — Net income — — — 565 565 Balances at June 30, 2022 12,839,118 $ 13 $ 4,431,970 $ ( 4,160,453 ) $ 271,530 Six Months Ended June 30, 2021 Total Common Stock Additional Accumulated Stockholders’ Shares Amount Paid-In Capital Deficit Equity Balances at December 31, 2020 12,792,586 $ 13 $ 4,430,924 $ ( 4,190,425 ) $ 240,512 Stock-based compensation — — 177 — 177 Issuance of common stock upon vesting of restricted stock 3,021 — — — — Net income — — — 3,389 3,389 Balances at March 31, 2021 12,795,607 13 4,431,101 ( 4,187,036 ) 244,078 Stock-based compensation — — 187 — 187 Issuance of common stock upon vesting of restricted stock 2,940 — — — — Net income — — — 13,970 13,970 Balances at June 30, 2021 12,798,547 $ 13 $ 4,431,288 $ ( 4,173,066 ) $ 258,235 See accompanying notes to the unaudited condensed consolidated financial statements. 3 SWK HOLDINGS CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Six Months Ended June 30, 2022 2021 Cash flows from operating activities: Net income $ 4,043 $ 17,359 Adjustments to reconcile net income to net cash provided by operating activities: Amortization of debt issuance costs 29 93 Deferred income taxes 1,257 4,369 Change in fair value of warrants 1,165 ( 892 ) Change in fair value of equity securities 547 ( 1,215 ) Change in fair value of acquisition-related contingent consideration — ( 147 ) Loan discount amortization and fee accretion ( 780 ) ( 1,130 ) Interest income paid-in-kind ( 1,599 ) ( 26 ) Stock-based compensation 251 364 Depreciation and amortization expense 1,330 2,493 Changes in operating assets and liabilities: Interest and accounts receivable ( 66 ) ( 728 ) Other assets ( 256 ) ( 477 ) Accounts payable and other liabilities ( 2,526 ) ( 813 ) Net cash provided by operating activities 3,395 19,250 Cash flows from investing activities: Investment in finance receivables ( 25,350 ) ( 20,100 ) Repayment of finance receivables 34,195 22,779 Corporate debt securities principal payments 21 31 Purchases of property and equipment ( 111 ) ( 671 ) Other 113 163 Net cash provided by investing activities 8,868 2,202 Cash flows from financing activities: Net payments on credit facility ( 8 ) ( 11,758 ) Payment of acquisition-related contingent consideration — ( 6,083 ) Net cash used in financing activities ( 8 ) ( 17,841 ) Net increase in cash and cash equivalents 12,255 3,611 Cash and cash equivalents at beginning of period 42,863 3,008 Cash and cash equivalents at end of period $ 55,118 $ 6,619 See accompanying notes to the unaudited condensed consolidated financial statements. 4 SWK HOLDINGS CORPORATION NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1. SWK Holdings Corporation and Summary of Significant Accounting Policies Nature of Operations SWK Holdings Corporation (the “Company”) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, the Company commenced its strategy of building a specialty finance and asset management business. In August 2019, the Company commenced a complementary strategy of building a pharmaceutical development, manufacturing and intellectual property licensing business. The Company’s operations comprise two reportable segments: “Finance Receivables” and “Pharmaceutical Development.” The Company allocates capital to each segment in order to generate income through the sales of life science products by third parties. The Company is headquartered in Dallas, Texas, and as of June 30, 2022, the Company had 34 full-time employees. The Company has net operating loss carryforwards (“NOLs”) and believes that the ability to utilize these NOLs is an important and substantial asset. However, at this time, under current law, the Company does not anticipate that the Finance Receivables and/or Pharmaceutical Development segments will generate sufficient income to permit the Company to utilize all of its NOLs prior to their respective expiration dates. As such, it is possible that the Company might pursue additional strategies that it believes might result in the ability to utilize more of the NOLs. As of August 3, 2022, the Company and its partners have executed transactions with 46 different parties under its specialty finance strategy, funding an aggregate of $649.6 million in various financial products across the life science sector. The Company’s portfolio includes senior and subordinated debt backed by royalties and synthetic royalties paid by companies in the life science sector, and purchased royalties generated by sales of life science products and related intellectual property. During 2019, the Company commenced its Pharmaceutical Development segment with the acquisition of Enteris BioPharma, Inc. (“Enteris”). Enteris is a clinical stage biopharmaceutical company offering innovative formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform. Since its founding in 2013, Enteris has advanced multiple internal and external programs leveraging Peptelligence®, which enables the oral delivery of molecules that are typically injected, including peptides and BCS Class II, III, and IV small molecules, in an enteric-coated tablet formulation. Peptelligence® utilizes a unique multifaceted approach to increase the solubility and absorption of peptides and small molecules, addressing the complex challenges regarding solubility and permeability of therapeutics with low oral bioavailability. Peptelligence® is protected by an extensive patent estate that extends until 2036. Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The consolidated financial statements include the accounts of all subsidiaries and affiliates in which the Company holds a controlling financial interest as of the financial statement date. Normally a controlling financial interest reflects ownership of a majority of the voting interests. The Company consolidates a variable interest entity (“VIE”) when it possesses both the power to direct the activities of the VIE that most significantly impact its economic performance and the Company is either obligated to absorb the losses that could potentially be significant to the VIE or the Company holds the right to receive benefits from the VIE that could potentially be significant to the VIE, after elimination of intercompany accounts and transactions. The Company owns interests in various partnerships and limited liability companies, or LLCs. The Company consolidates its investments in these partnerships or LLCs where the Company, as the general partner or managing member, exercises effective control, even though the Company’s ownership may be less than 50 percent, the related governing agreements provide the Company with broad powers, and the other parties do not participate in the management of the entities and do not effectively have the ability to remove the Company. The Company has reviewed each of the underlying agreements to determine if it has effective control. If circumstances change and it is determined this control does not exist, any such investment would be recorded using the equity method of accounting. Although this would change individual line items within the Company’s consolidated financial statements, it would have no effect on its operations and/or total stockholders’ equity attributable to the Company. 5 Unaudited Interim Financial Information The unaudited condensed consolidated financial statements have been prepared by the Company and reflect all normal, recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the interim financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the year ending December 31, 2022. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted under the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 25, 2022. Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of accounts receivable; impairment of finance receivables; long-lived assets; property and equipment; intangible assets; goodwill; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable. The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. Segment Information The Company earns revenues from its two U.S.-based business segments: its specialty finance and asset management business offering customized financing solutions to a broad range of life-sciences companies, and its business offering oral therapeutic formulation solutions built around Enteris’ pharmaceutical Peptelligence® platform, which enables the oral delivery of molecules that are typically injected, including peptides and BCS Class II, III, and IV small molecules in an enteric-coated tablet formulation. Revenue Recognition The Company’s Pharmaceutical Development segment enters into collaboration and licensing agreements with strategic partners, under which it may exclusively license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Deferred revenue includes amounts that have been billed per the contractual terms but have not been recognized as revenue. The Company classifies as current the portion of deferred revenue that is expected to be recognized within one year from the balance sheet date and is included in accounts payable and accrued liabilities in the unaudited condensed consolidated balance sheets. 6 Research and Development Research and development expenses include the costs associated with internal research and development and research and development conducted for the Company by third parties. These costs primarily consist of salaries, pre-clinical and clinical trials, outside consultants, and supplies. All research and development costs discussed above are expensed as incurred. Third-party expenses reimbursed under research and development contracts, which are not refundable, are recorded as a reduction to pharmaceutical manufacturing research and development expense in the consolidated statements of income. Recent Accounting Pronouncements In March 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2022-02, “Financial Instruments - Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures,” which updates the requirements for accounting for credit losses under Accounting Standards Codification 326, eliminates the accounting guidance on troubled debt restructurings for creditors, and enhances creditors’ disclosure requirements related to loan refinancings and restructurings for borrowers experiencing financial difficulty. The ASU also amends the guidance on vintage disclosures to require disclosure of gross write-offs by year of origination. The amendments are effective in periods beginning after December 15, 2022 using either a prospective or modified retrospective transition. Early adoption of certain or all of the amendments is permitted. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326).” This ASU adds an impairment model, known as the current expected credit loss (“CECL”) model, that is based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses, which the FASB believes will result in more timely recognition of losses. This ASU describes the impairment allowance as a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be measured in a manner similar to current GAAP; however, the amendments in this update require that credit losses be presented as an allowance rather than as a write-down, which will allow an entity the ability to record reversals of credit losses in current period net income. On November 15, 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates,” which finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies. Under ASU 2019-10, the effective date for implementation of CECL for smaller reporting companies was extended to fiscal years, and interim periods within those years, beginning after December 15, 2022. The Company is currently evaluating the new guidance but believes it is likely to incur more upfront losses on its portfolio under the new CECL model. In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848),” which provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate reform if certain criteria are met. These transactions include: (i) contract modifications, (ii) hedging relationships, and (iii) sales or transfers of debt securities classified as held-to-maturity. ASU 2020-04 was effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2024. The Company has identified existing loans that reference LIBOR and is in the process of evaluating alternatives in each situation. The Company expects that it will elect to apply some of the expedients and exceptions provided in ASU 2020-04 and does not believe the adoption of this standard will have a material impact on the Company’s consolidated financial statements. 7 Note 2. Net Income per Share Basic net income per share is computed using the weighted-average number of outstanding shares of common stock. Diluted net income per share is computed using the weighted-average number of outstanding shares of common stock, and when dilutive, shares of common stock issuable upon exercise of options and warrants deemed outstanding using the treasury stock method. The following table shows the computation of basic and diluted net income per share for the following periods (in thousands, except per share amounts): Schedule of Basic and Diluted Earning per Share Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income $ 565 $ 13,970 $ 4,043 $ 17,359 Denominator: Weighted-average shares outstanding 12,835 12,796 12,833 12,794 Effect of dilutive securities 50 38 49 28 Weighted-average diluted shares 12,885 12,834 12,882 12,822 Basic net income per share $ 0.04 $ 1.09 $ 0.32 $ 1.36 Diluted net income per share $ 0.04 $ 1.09 $ 0.31 $ 1.35 For the three months ended June 30, 2022 and 2021, outstanding options to purchase shares of common stock and outstanding shares of restricted stock in an aggregate of approximately 308,000 and 391,000 , respectively, have been excluded from the calculation of diluted net income per share, as such securities were anti-dilutive. For the six months ended June 30, 2022 and 2021, outstanding options to purchase shares of common stock and outstanding shares of restricted stock in an aggregate of approximately 309,000 and 401,000 , respectively, have been excluded from the calculation of diluted net income per share, as all such securities were anti-dilutive. 8 Note 3. Finance Receivables, Net Finance receivables are reported at their determined principal balances net of any unearned income, cumulative charge-offs and unamortized deferred fees and costs. Unearned income and deferred fees and costs are amortized to interest income based on all cash flows expected using the effective interest method. As of June 30, 2022 and December 31, 2021, the Company had a credit loss allowance of $8.4 million. Of the total $8.4 million, $ 1.2 million and $ 0.6 million are associated with the Company’s Cambia® and Besivance® royalties, respectively. The remaining $ 6.6 million is related to the ABT Molecular Imaging, Inc., now known as Best ABT, Inc. (“Best”), second lien term loan that was recognized in order to reflect the Best royalty at its estimated fair value. Approximately $23,000 of cash receipts received from the Company’s Besivance® royalty during the six months ended June 30, 2022 were applied toward the allowance for credit losses. The carrying values of finance receivables are as follows (in thousands): Schedule of carrying value of finance receivables June 30, 2022 December 31, 2021 Term loans $ 133,004 $ 136,312 Royalty purchases 50,220 53,629 Total before allowance for credit losses 183,224 189,941 Allowance for credit losses ( 8,365 ) ( 8,388 ) Total carrying value $ 174,859 $ 181,553 The following table presents nonaccrual and performing finance receivables by portfolio segment, net of credit loss allowance (in thousands): Schedule of analysis of nonaccrual and performing loans by portfolio segment June 30, 2022 December 31, 2021 Nonaccrual Performing Total Nonaccrual Performing Total Term loans $ 9,789 $ 123,215 $ 133,004 $ 18,288 $ 118,024 $ 136,312 Royalty purchases, net of credit loss allowance 3,127 38,728 41,855 3,362 41,879 45,241 Total carrying value $ 12,916 $ 161,943 $ 174,859 $ 21,650 $ 159,903 $ 181,553 As of June 30, 2022, the Company had two finance receivables in nonaccrual status: (1) the term loan to Flowonix Medical, Inc. (“Flowonix”), with a net carrying value of $ 9.8 million and (2) the Best royalty, with a net carrying value of $ 3.1 million . Although in nonaccrual status, the Flowonix term loan was not considered impaired as of June 30, 2022 and December 31, 2021. The Company collected $0.6 million on its nonaccrual finance receivables during the six months ended June 30, 2022. Note 4. Marketable Investments Investments in available-for-sale corporate debt securities and equity securities as of June 30, 2022 and December 31, 2021 consist of the following (in thousands): Schedule of marketable investments June 30, 2022 December 31, 2021 Corporate debt securities $ 98 $ 119 Equity securities 487 1,034 Total marketable investments $ 585 $ 1,153 9 The amortized cost basis amounts, gross unrealized holding gains, gross unrealized holding losses and fair values of available-for-sale corporate debt securities as of June 30, 2022 and December 31, 2021, are as follows (in thousands): Schedule of marketable investments Amortized Cost Gross Unrealized Gains Gross Unrealized Loss Fair Value June 30, 2022 $ 98 $ — $ — $ 98 December 31, 2021 $ 119 $ — $ — $ 119 The following table presents unrealized net (loss) gain on equity securities during the three and six months ended June 30, 2022 and 2021 (in thousands): Schedule of Proceeds from sales, gross unrealized gains and gross unrealized losses for available-for-sale securities Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Unrealized net (loss) gain on equity securities reflected in the unaudited condensed consolidated statements of income $ ( 519 ) $ 283 $ ( 547 ) $ 1,215 Note 5. Intangible Assets The following table summarizes the gross book value, accumulated amortization and net book value balances of intangible assets as of June 30, 2022 and December 31, 2021 (in thousands): Schedule of Intangible Assets June 30, 2022 December 31, 2021 Gross Book Value Accumulated Amortization Net Book Value Gross Book Value Accumulated Amortization Net Book Value Licensing Agreement (1) $ 29,400 $ 20,680 $ 8,720 $ 29,400 $ 19,780 $ 9,620 Trade names and trademarks 210 60 150 210 50 160 Customer relationships 240 68 172 240 56 184 Total intangible assets $ 29,850 $ 20,808 $ 9,042 $ 29,850 $ 19,886 $ 9,964 (1) Prior to the acquisition, Enteris entered into a non-exclusive commercial license agreement (the “License Agreement”) with Cara Therapeutics, Inc. (“Cara”), for oral formulation rights to Enteris’ Peptelligence® technology to develop and commercialize Oral KORSUVA TM in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the licensed territory. Amortization expense related to intangible assets was $ 0.4 million and $ 0.7 million for the three months ended June 30, 2022 and 2021, respectively. Amortization expense related to intangible assets was $ 0.9 million and $ 2.3 million for the six months ended June 30, 2022 and 2021, respectively. The estimated future amortization expense related to intangible assets as of June 30, 2022 is as follows (in thousands): Schedule of Intangible Asset Amortization Expense Fiscal Year Amount Remainder of 2022 $ 851 2023 1,703 2024 1,546 2025 1,076 2026 1,076 Thereafter 2,790 Total $ 9,042 10 Note 6. Commitments and Contingencies Contingent Consideration The Company recorded contingent consideration related to the 2019 acquisition of Enteris and sharing of certain milestone and royalties due to Enteris pursuant to the License Agreement. Contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved, with changes in the estimated fair value recognized in earnings. The estimated fair value of contingent consideration as of June 30, 2022 and December 31, 2021 was $ 8.5 million . The Company did not recognize a change in the estimated fair value of its contingent consideration during the six months ended June 30, 2022. The Company recognized a $0.1 million gain on the change in fair value of its contingent consideration during the six months ended June 30, 2021. Unfunded Commitments As of June 30, 2022, the Company’s unfunded commitments were as follows (in millions): Schedule of Unfunded Commitments Trio Healthcare Ltd. Loan $ 1.4 Total unfunded commitments $ 1.4 Unfunded commitments are contingent upon reaching an established revenue threshold or other performance metrics on or before a specified date or period of time per the terms of the royalty purchase or credit agreements, and in the case of loan transactions, are only subject to being advanced as long as an event of default does not exist. 11 Note 7. Fair Value Measurements The Company measures and reports certain financial and non-financial assets and liabilities on a fair value basis. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). GAAP specifies a three-level hierarchy that is used when measuring and disclosing fair value. The fair value hierarchy gives the highest priority to quoted prices available in active markets (i.e., observable inputs) and the lowest priority to data lacking transparency (i.e., unobservable inputs). An instrument’s categorization within the fair value hierarchy is based on the lowest level of significant input to its valuation. The following is a description of the three hierarchy levels. Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Active markets are considered to be those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. This category includes quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in inactive markets. Level 3 Unobservable inputs are not corroborated by market data. This category is comprised of financial and non-financial assets and liabilities whose fair value is estimated based on internally developed models or methodologies using significant inputs that are generally less readily observable from objective sources. Transfers into or out of any hierarchy level are recognized at the end of the reporting period in which the transfers occurred. There were no transfers between any levels during the six months ended June 30, 2022. The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying unaudited condensed consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments, other than investment in affiliates. Following are descriptions of the valuation methodologies used to measure material assets and liabilities at fair value and details of the valuation models, key inputs to those models and significant assumptions utilized. Cash and cash equivalents The carrying amounts reported in the balance sheet for cash and cash equivalents approximate those assets’ fair values. Marketable Investments Certain common equity securities are reported at fair value utilizing Level 1 inputs (exchange quoted prices). Finance Receivables The fair values of finance receivables are estimated using discounted cash flow analyses, using market rates at the balance sheet date that reflect the credit and interest rate-risk inherent in the finance receivables. Projected future cash flows are calculated based upon contractual maturity or call dates, projected repayments and prepayments of principal. These receivables are classified as Level 3. Finance receivables are not measured at fair value on a recurring basis, but estimates of fair value are reflected below. Contingent Consideration The Company recorded contingent consideration related to the 2019 acquisition of Enteris and sharing of certain milestone and royalties due to Enteris pursuant to the License Agreement. The fair value measurements of contingent consideration obligations arising from business combinations are classified as Level 3 estimates under the fair value hierarchy as these items have been valued using unobservable inputs. These inputs include: (a) the estimated amount and timing of projected cash flows; (b) the probability of the achievement of the factors on which the contingency is based; and (c) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement. 12 Marketable Investments and Derivative Securities Marketable Investments If active market prices are available, fair value measurement is based on quoted active market prices and, accordingly, these securities would be classified as Level 1. If active market prices are not available, fair value measurement is based on observable inputs other than quoted prices included within Level 1, such as prices for similar assets or broker quotes utilizing observable inputs, and accordingly these securities would be classified as Level 2. If market prices are not available and there are no observable inputs, then fair value would be estimated by using valuation models including discounted cash flow methodologies, commonly used option-pricing models and broker quotes. Such securities would be classified as Level 3, if the valuation models and broker quotes are based on inputs that are unobservable in the market. If fair value is based on broker quotes, the Company checks the validity of received prices based on comparison to prices of other similar assets and market data such as relevant bench mark indices. Available-for-sale securities are measured at fair value on a recurring basis, while securities with no readily available fair market value are not, but estimates of fair value are reflected below. Derivative Securities For exchange-traded derivatives, fair value is based on quoted market prices, and accordingly, would be classified as Level 1. For non-exchange traded derivatives, fair value is based on option pricing models and are classified as Level 3. The following table presents financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2022 (in thousands): Schedule of fair value assets measured on recurring basis Total Carrying Value in Consolidated Balance Sheets Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Financial Assets Warrant assets $ 2,481 $ — $ — $ 2,481 Marketable investments 585 487 — 98 Financial Liabilities Contingent consideration payable $ 8,530 $ — $ — $ 8,530 The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 (in thousands): Total Carrying Value in Consolidated Balance Sheets Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Financial Assets Warrant assets $ 3,419 $ — $ — $ 3,419 Marketable investments 1,153 1,034 — 119 Financial Liabilities Contingent consideration payable $ 8,530 $ — $ — $ 8,530 13 The changes in fair value of the warrant assets during the six months ended June 30, 2022 and 2021 were as follows (in thousands): Schedule of fair value assets measured on recurring basis unobservable input reconciliation June 30, 2022 June 30, 2021 Fair value - December 31, 2021 $ 3,419 Fair value - December 31, 2020 $ 2,972 Issued 227 Issued — Canceled — Canceled — Change in fair value ( 1,165 ) Change in fair value 892 Fair value - June 30, 2022 $ 2,481 Fair value - June 30, 2021 $ 3,864 The Company holds warrants issued to the Company in conjunction with certain term loan investments. These warrants meet the definition of a derivative and are included in the unaudited condensed consolidated balance sheets. The fair values for warrants outstanding, which do not have a readily determinable value, are measured using the Black-Scholes option pricing model. The following ranges of assumptions were used in the models to determine fair value: Schedule of weighted average assumptions June 30, 2022 December 31, 2021 Dividend rate range — — Risk-free rate range 2.9 % to 3.0 % 0.97 % to 1.44 % Expected life (years) range 2.1 to 6.7 2.6 to 7.0 Expected volatility range 52.6 % to 147.5 % 60.2 % to 142.0 % As of June 30, 2022 and December 31, 2021, the Company had two royalties, Best and Cambia®, that were deemed to be impaired based on reductions in carrying values in prior periods. The following table presents these royalties measured at fair value on a nonrecurring basis as of June 30, 2022 and December 31, 2021 (in thousands): Schedule of fair value assets and liabilities measured on nonrecurring basis Total Carrying Value in Consolidated Balance Sheets Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) June 30, 2022 $ 4,604 $ — $ — $ 4,604 December 31, 2021 $ 5,612 $ — $ — $ 5,612 There were no liabilities measured at fair value on a nonrecurring basis as of June 30, 2022 and December 31, 2021. The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying unaudited condensed consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments measured at fair value on a recurring and non-recurring basis. 14 Schedule of fair value by balance sheet grouping As of June 30, 2022 (in thousands): Carrying Value Fair Value Level 1 Level 2 Level 3 Financial Assets Cash and cash equivalents $ 55,118 $ 55,118 $ 55,118 $ — $ — Finance receivables 174,859 174,859 — — 174,859 Marketable investments 585 585 487 — 98 Warrant assets 2,481 2,481 — — 2,481 Financial Liabilities Contingent consideration payable $ 8,530 $ 8,530 $ — $ — $ 8,530 As of December 31, 2021 (in thousands): Carrying Value Fair Value Level 1 Level 2 Level 3 Financial Assets Cash and cash equivalents $ 42,863 $ 42,863 $ 42,863 $ — $ — Finance receivables 181,553 181,553 — — 181,553 Marketable investments 1,153 1,153 1,034 — 119 Warrant assets 3,419 3,419 — — 3,419 Financial Liabilities Contingent consideration payable $ 8,530 $ 8,530 $ — $ — $ 8,530 Note 8. Revenue Recognition The Company’s Pharmaceutical Development segment recognizes revenues received from contracts with its customers by revenue source, as the Company believes it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow. The Company’s Finance Receivables segment does not have any revenues received from contracts with customers. The following table provides the contract revenue recognized by revenue source for the three and six months ended June 30, 2022 and 2021 (in thousands): Schedule of Revenue Recognized by Revenue Source Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Pharmaceutical Development Segment License Agreement $ 16 $ 10,431 $ 132 $ 10,610 Pharmaceutical Development and other 98 30 698 545 Total contract revenue $ 114 $ 10,461 $ 830 $ 11,155 The Company’s contract liabilities represent advance consideration received from customers and are recognized as revenue when the related performance obligation is satisfied. 15 The Company’s contract liabilities are presented as deferred revenues and are included in accounts payable and accrued liabilities in the consolidated balance sheets (in thousands): Schedule of Company's Contract Liabilities June 30, 2022 December 31, 2021 Pharmaceutical Development Segment Deferred revenue $ 56 $ 185 Total contract liabilities $ 56 $ 185 During the six months ended June 30, 2022, the Company recognized $ 0.1 million of 2021 deferred revenue from satisfaction of performance obligations. The Company did not have any contract assets nor did it have any contract liabilities related to the License Agreement as of June 30, 2022 or December 31, 2021. 16 Note 9. Segment Information Selected financial and descriptive information is required to be provided about reportable operating segments, considering a “management approach” concept as the basis for identifying reportable segments. The management approach is based on the way that management organizes the segments within the Company for making operating decisions, allocating resources, and assessing performance. Consequently, the segments are evident from the structure of the Company’s internal organization, focusing on financial information that the Company’s chief executive officer uses to make decisions about the Company’s operating matters. As described in Note 1, the Company has determined it has two reportable segments: Finance Receivables and Pharmaceutical Development, and each are individually managed and provide separate services. Revenues by segment represent revenues earned on the services offered within each segment. The Company does not report assets by reportable segment, nor does the Company report results by geographic region, as these metrics are not used by the Company’s chief executive officer in assessing performance or allocating resources to the segments. Segment performance is evaluated based on several factors, including income (loss) from continuing operations before income taxes. Management uses this measure of net income (loss) to evaluate segment performance because the Company believes this measure is indicative of performance trends and the overall earnings potential of each segment. The following tables present financial information for the Company’s reportable segments for the periods indicated (in thousands): Schedule of Reportable Segments Three Months Ended June 30, 2022 Finance Receivables Pharmaceutical Development and Other Holding Company and Other Consolidated Revenue $ 6,828 $ 114 $ — $ 6,942 Interest expense 80 — — 80 Manufacturing, research and development — 1,480 — 1,480 Depreciation and amortization expense — 625 1 626 General and administrative 2 905 2,111 3,018 Other expense, net ( 991 ) — — ( 991 ) Income tax expense — — 182 182 Net income (loss) 5,755 ( 2,896 ) ( 2,294 ) 565 Three Months Ended June 30, 2021 Finance Receivables Pharmaceutical Development and Other Holding Company and Other Consolidated Revenue $ 11,805 $ 10,461 $ — $ 22,266 Interest expense 94 — — 94 Manufacturing, research and development — 1,542 — 1,542 Depreciation and amortization expense — 809 2 811 Change in fair value of acquisition-related contingent consideration — ( 147 ) — ( 147 ) General and administrative 950 983 1,427 3,360 Other income, net 892 — — 892 Income tax expense — — 3,528 3,528 Net income (loss) 11,653 7,274 ( 4,957 ) 13,970 17 Six Months Ended June 30, 2022 Finance Receivables Pharmaceutical Development and Other Holding Company and Other Consolidated Revenue $ 17,243 $ 350 $ — $ 17,593 Other revenue — 480 — 480 Interest expense 160 — — 160 Manufacturing, research and development — 3,381 — 3,381 Depreciation and amortization expense — 1,329 1 1,330 General and administrative 104 1,940 4,134 6,178 Other expense, net ( 1,712 ) — — ( 1,712 ) Income tax expense — — 1,269 1,269 Net income (loss) 15,267 ( 5,820 ) ( 5,404 ) 4,043 Six Months Ended June 30, 2021 Finance Receivables Pharmaceutical Development and Other Holding Company and Other Consolidated Revenue $ 20,484 $ 10,659 $ — $ 31,143 Other revenue — 496 — 496 Interest expense 239 — — 239 Manufacturing, research and development — 3,090 — 3,090 Depreciation and amortization expense — 2,490 3 2,493 Change in fair value of acquisition-related contingent consideration — ( 147 ) — ( 147 ) General and administrative 1,134 2,088 3,023 6,245 Other income, net 2,107 — — 2,107 Income tax expense — — 4,467 4,467 Net income (loss) 21,218 3,634 ( 7,493 ) 17,359 Included in Holding Company and Other are the expenses of the parent holding company and certain other enterprise-wide overhead costs, including public company costs and non-Enteris corporate employees, which have been included for purposes of reconciling to the consolidated amounts. Note 10. Subsequent Events Exeevo, Inc. On July 1, 2022, SWK Funding, a subsidiary of the Company, entered into a credit agreement pursuant to which SWK Funding provided to Exeevo, Inc. (“Exeevo”) a term loan in the amount of $ 7.5 million . SWK Funding funded $ 5.0 million at closing with the remaining $ 2.5 million becoming available upon Exeevo’s satisfaction of certain future conditions. The loan matures on July 1, 2027 . In connection with the loan, SWK Funding also received a warrant to purchase 930 shares of Exeevo common stock. Beleodaq® Royalty On July 1, 2022, SWK Funding received $ 4.3 million for the payoff of the Beleodaq® royalty. Trio Healthcare Ltd., (Ostomy Products Royalty) On July 25, 2022, SWK Funding received $ 6.1 million for the payoff of the Ostomy Products Royalty. 18 ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements, and the MD&A included in our Annual Report on Form 10-K for the year ended December 31, 2021 (“Annual Report”), as well as our unaudited condensed consolidated financial statements and the accompanying notes included in this report. Environmental, Social and Governance As overseers of risk and stewards of long-term enterprise value, our management and Board play a vital role in assessing, identifying and understanding the potential impact and related risks of environmental, social and governance (“ESG”) issues on the organization’s operating model. Our Board and management are committed to identifying those ESG issues most likely to impact business operations and growth by focusing our investment strategy around supporting innovative, growth-oriented companies in the life sciences industry that maximize both social and investment value. Among the ESG issues we support within the Company, we are committed to recruiting, motivating and developing a diversity of talent. We promote and foster a company culture where every voice is welcome, heard and respected, regardless of age, gender, race, religion, sexual orientation, physical conditions, cultural background or country of origin. Our commitment to ESG initiatives is an endeavor both the Board and management undertake for the general betterment of those both inside and outside the Company. The nature of our business supports environmental sustainability by being mindful of products we and our partners use in our businesses. We promote recycling to reduce landfill, and we offer our employees a hybrid work model, which allows employees the flexibility to work remotely, thereby reducing the carbon output from commuting in cars or buses. Overview We have organized our operations into two segments: Finance Receivables and Pharmaceutical Development. These segments reflect the way the Company evaluates its business performance and manages its operations. Please refer to Item 1. Financial Statements, Note 9 of the notes to the unaudited condensed consolidated financial statements for further information regarding segment information. 19 Finance Receivables Portfolio Overview The table below provides an overview of our outstanding finance receivables transactions as of, and for the three and six months ended June 30, 2022 (in thousands, except rate, share and per share data). Revenue Recognized Royalty Purchases Licensed Technology Footnote Funded Amount GAAP Balance Q2 YTD Beleodaq® Oncology treatment (1) $ 7,600 $ 4,242 $ 470 $ 772 Besivance® Ophthalmic antibiotic (2) 6,000 — 3 13 Best ABT, Inc. Oncology diagnosis (3), (4) 5,784 3,127 — — Coflex®/Kybella®/Zalviso® Spinal stenosis/submental fullness 4,350 4,001 167 292 Cambia® NSAID migraine treatment (3) 8,500 1,477 (44 ) (59 ) Forfivo XL® Depressive disorder treatment 6,000 1,416 224 672 Ideal Implant, Inc. Aesthetics 3,000 3,259 134 268 Iluvien® Diabetic macular edema 16,501 15,916 536 1,121 Narcan® Opioid overdose treatment 17,500 497 236 1,660 Ostomy Products Royalty Ostomy products (1) 3,900 3,961 18 181 Veru, Inc. Women’s health 10,000 3,959 237 525 Revenue Recognized Term Loans Type Footnote Maturity Date Principal GAAP Balance Rate Q2 YTD 4Web, Inc. First lien 06/03/23 $ 27,797 $ 29,876 15.8 % $ 1,088 $ 2,144 AOTI, Inc. First lien 03/21/27 12,000 11,919 11.0 % 375 414 Acer Therapeutics, Inc. First lien 03/04/24 6,500 6,488 12.0 % 416 546 Acerus Pharmaceuticals Corporation First lien (5) 10/11/23 — — 12.0 % — 538 B&D Dental Corporation First lien (5) 12/10/18 — — 14.0 % — 2,401 BIOLASE, Inc. First lien 05/31/25 13,300 13,633 10.5 % 461 906 Biotricity, Inc. First lien 12/26/26 12,000 11,823 11.5 % 400 786 Epica International, Inc. First lien 07/23/24 12,000 12,291 9.5 % 359 712 eTon Pharmaceuticals, Inc. First lien 11/13/24 6,615 6,615 10.0 % 202 445 Flowonix Medical, Inc. First lien (4), (6) 12/23/25 10,428 9,789 14.0 % — — Keystone Dental Group First lien (5) 08/01/23 — — 11.5 % 440 888 MolecuLight, Inc. First lien 12/29/26 10,000 9,951 12.5 % 349 623 Sincerus Pharmaceuticals, Inc. First lien 03/19/26 12,300 12,504 13.0 % 491 903 Trio Healthcare Ltd. First lien 07/01/26 8,150 8,115 12.5 % 266 492 Revenue Recognized Cost Method Investment Licensed Technology Footnote Maturity Date Principal GAAP Balance Rate Q2 YTD Tissue Regeneration Therapeutics, Inc. Umbilical cord banking (4) N/A $ 3,491 $ 3,491 N/A $ — $ — 20 Income (Loss) Recognized Marketable Investments Number of Shares Footnote Funded Amount GAAP Balance Q2 YTD Secured Royalty Financing (Marketable Investment) N/A (4) $ 3,000 $ 98 $ — $ — Bioventus, Inc. Common Stock 71,361 N/A 487 (519 ) (547 ) Epica International, Inc. 25,000 N/A — — — Sincerus Pharmaceuticals, Inc. 26,575 N/A — — — Income (Loss) Recognized Warrants to Purchase Stock Number of Shares Footnote Exercise Price per Share ($) GAAP Balance Q2 YTD 4Web, Inc. TBD $ — $ — $ — $ — AOTI, Inc. 92,490 — — — — Acer Therapeutics, Inc. 150,000 2.46 99 (131 ) (127 ) Acerus Pharmaceuticals Corporation 7,764,004 0.053 CAD 52 (178 ) (49 ) BIOLASE, Inc. 22,039 0.39 63 (67 ) (121 ) Biotricity, Inc. 57,536 6.26 61 (16 ) (116 ) CeloNova BioSciences, Inc. TBD (7) — — — — DxTerity Diagnostics, Inc. 2,019,231 (7) — — — — Epica International, Inc. TBD — — — — eTon Pharmaceuticals, Inc. 51,238 5.86 36 (62 ) (59 ) eTon Pharmaceuticals, Inc. 18,141 6.62 13 (22 ) (21 ) EyePoint Pharmaceuticals, Inc. 40,910 11.00 134 (137 ) (143 ) EyePoint Pharmaceuticals, Inc. 7,773 19.30 18 (22 ) (23 ) Flowonix Medical, Inc. 155,561 (4), (6) — — — — Harrow Health, Inc. 373,847 (2) 2.08 2,005 163 (506 ) Total Revenue Assets Q2 YTD Total finance receivables $ 174,859 $ 6,828 $ 17,243 Total marketable investments 585 N/A N/A Cost method investment 3,491 N/A N/A Fair value of warrant assets 2,481 N/A N/A Total assets/revenues $ 181,416 $ 6,828 $ 17,243 (1) Royalty was paid off during the third quarter of 2022. (2) US royalty was paid off during the year ended December 31, 2021. SWK continues to receive insignificant royalties on international sales. (3) Investment considered impaired. (4) Investment on nonaccrual. (5) Loan was paid off during the six months ended June 30, 2022. (6) Flowonix is evaluating strategic alternatives for the business. (7) Loan was paid off during the year ended December 31, 2021. Unless otherwise specified, our senior secured debt assets generally are repaid by a revenue interest that is charged on a company’s quarterly net sales and royalties. 21 Critical Accounting Policies and Estimates Our critical accounting policies and estimates are described in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report. We believe there have been no new critical accounting policies or material changes to our existing critical accounting policies and estimates during the six months ended June 30, 2022, compared to those discussed in our Annual Report. Recent Accounting Pronouncements Refer to Part I. Financial Information, Item 1. Financial Statements, Note 1 of the notes to the unaudited condensed consolidated financial statements for a listing of recent accounting pronouncements and their potential impact to our consolidated financial statements. Comparison of the Three Months Ended June 30, 2022 and 2021 ( in millions ) Three Months Ended June 30, 2022 2021 Change Revenues $ 6.9 $ 22.3 $ (15.4 ) Interest expense 0.1 0.1 — Pharmaceutical manufacturing, research and development expense 1.5 1.5 — Change in fair value of acquisition-related contingent consideration — (0.1 ) 0.1 Depreciation and amortization expense 0.6 0.8 (0.2 ) General and administrative 3.0 3.4 (0.4 ) Other (expense) income, net (1.0 ) 0.9 (1.9 ) Income tax expense 0.2 3.5 (3.3 ) Net income 0.6 14.0 (13.4 ) Revenues Revenues decreased to $6.9 million for the three months ended June 30, 2022 from $22.3 million for the three months ended June 30, 2021. The $15.4 million decrease in revenue consisted of a $10.3 million decrease in Pharmaceutical Development segment revenue and a $5.0 million decrease in Finance Receivables segment revenue. The decrease in Pharmaceutical Development segment revenue included $10.0 million of milestone revenue related to Enteris’ License Agreement with Cara received during the three months ended June 30, 2021, which did not recur during the three months ended June 30, 2022. The $5.0 million decrease in Finance Receivables segment revenues primarily consists of a $3.1 million decrease in interest and fees earned on finance receivables that were either paid off or paid down since the second quarter of 2021 and a $4.0 million decrease in net royalty income primarily due to the achievement of return premiums that caused a step down in royalty rates. The decrease in revenue was partially offset by a $2.1 million increase in interest and fees earned due to funding new and existing loans. Interest Expense Interest expense consists of interest accrued on our revolving line of credit, unused line of credit and maintenance fees, as well as amortization of debt issuance costs. Interest expense for both the three months ended June 30, 2022 and 2021 was $0.1 million, respectively. Pharmaceutical Manufacturing, Research and Development Expense Pharmaceutical manufacturing, research and development expense for both the three months ended June 30, 2022 and 2021 was $1.5 million, respectively. Pharmaceutical manufacturing, research and development expense primarily consists of manufacturing materials for our pipeline projects and clinical trials. 22 Depreciation and Amortization The $0.2 million decrease in depreciation and amortization expense for the three months ended June 30, 2022 primarily consists of a decrease in amortization expense related to the intangible assets of Enteris. Amortization expense is aligned with the expected future cash flows of the intangible assets. General and Administrative General and administrative expenses consist primarily of compensation; stock-based compensation and related costs for management, staff and Board; legal and audit expenses; and corporate governance expenses. General and administrative expenses decreased to $3.0 million for the three months ended June 30, 2022 from $3.4 million for the three months ended June 30, 2021. The $0.4 million decrease was primarily due to a $0.4 million decrease in corporate strategic planning and related board fees and a $0.2 million decrease in the performance-based bonus accrual. The decrease was partially offset by a $0.2 million increase in legal fees related to corporate governance. Other (Expense) Income, Net Other expense, net for three months ended June 30, 2022 reflected a net aggregate fair market value loss of $1.0 million on our warrant derivatives and Bioventus common stock. Other income, net for three months ended June 30, 2021 reflected a net fair market value gain of $0.6 million on our warrant derivatives and a net fair market value gain of $0.3 million on our Misonix common stock, which was tendered in October 2021 in exchange for $1.9 million in cash and 71,361 shares of Bioventus common stock. Income Tax Expense During the three months ended June 30, 2022 and 2021, we recognized income tax expense of $0.2 million and $3.5 million, respectively. The $3.3 million decrease in income tax expense is a result of lower taxable income when compared to the same period of 2021. Comparison of the Six Months Ended June 30, 2022 and 2021 ( in millions ) Six Months Ended June 30, 2022 2021 Change Revenues $ 18.1 $ 31.6 $ (13.5 ) Interest expense 0.2 0.2 — Pharmaceutical manufacturing, research and development expense 3.4 3.1 0.3 Change in fair value of acquisition-related contingent consideration — (0.1 ) 0.1 Depreciation and amortization expense 1.3 2.5 (1.2 ) General and administrative 6.2 6.2 — Other (expense) income, net (1.7 ) 2.1 (3.8 ) Income tax expense 1.3 4.5 (3.2 ) Net income 4.0 17.4 (13.4 ) 23 Revenues Revenues decreased to $18.1 million for the six months ended June 30, 2022 from $31.6 million for the six months ended June 30, 2021. The $13.5 million decrease in revenue consisted of a $10.3 million decrease in Pharmaceutical Development segment revenue and a $3.2 million decrease in Finance Receivables segment revenue. The decrease in Pharmaceutical Development segment revenue included $10.0 million of milestone revenue related to Enteris’ License Agreement with Cara received during the six months ended June 30, 2021, which did not recur during the six months ended June 30, 2022. The $3.2 million decrease in Finance Receivables segment revenues primarily consists of a $5.0 million decrease in interest and fees earned on finance receivables that were either paid off or paid down since the second quarter of 2021 and a $3.8 million decrease in net royalty income primarily due to the achievement of return premiums that caused a step down in royalty rates. The decrease in revenue was partially offset by a $3.4 million increase in interest and fees earned due to funding new and existing loans and a $2.4 million increase in interest and fees earned on the payoff of a term loan during the six months ended June 30, 2022. Interest Expense Interest expense consists of interest accrued on our revolving line of credit, unused line of credit and maintenance fees, as well as amortization of debt issuance costs. Interest expense for both the six months ended June 30, 2022 and 2021 was $0.2 million, respectively. Pharmaceutical Manufacturing, Research and Development Expense Pharmaceutical manufacturing, research and development expense increased from $3.1 million for the six months ended June 30, 2021 to $3.4 million for the six months ended June 30, 2022. The $0.3 million increase was primarily due to an increase in manufacturing materials for pipeline projects and clinical trials. Depreciation and Amortization The $1.2 million decrease in depreciation and amortization expense for the six months ended June 30, 2022 primarily consists of a decrease in amortization expense related to the intangible assets of Enteris. Amortization expense is aligned with the expected future cash flows of the intangible assets. General and Administrative General and administrative expenses consist primarily of compensation; stock-based compensation and related costs for management, staff and Board; legal and audit expenses; and corporate governance expenses. General and administrative expenses for both the six months ended June 30, 2022 and 2021 was $6.2 million. Other (Expense) Income, Net Other expense, net for six months ended June 30, 2022 reflected a net aggregate fair market value loss of $1.7 million on our warrant derivatives and Bioventus common stock. Other income, net for six months ended June 30, 2021 reflected a net fair market value gain of $0.9 million on our warrant derivatives and a net fair market value gain of $1.2 million on our Misonix common stock, which was tendered in October 2021 in exchange for $1.9 million in cash and 71,361 shares of Bioventus common stock. Income Tax Expense During the six months ended June 30, 2022 and 2021, we recognized income tax expense of $1.3 million and $4.5 million, respectively. The $3.2 million decrease in income tax expense is a result of lower taxable income when compared to the same period of 2021. Liquidity and Capital Resources As of June 30, 2022, we had $55.1 million in cash and cash equivalents, compared to $42.9 million in cash and cash equivalents as of December 31, 2021. The primary driver of the $12.3 million increase in our cash balance was $49.0 million of interest, fees, principal and royalty payments received on our finance receivables and $0.6 million of customer payments generated by our Pharmaceutical Development segment. The increase in our cash balance was partially offset by $25.0 million of investment funding, net of deferred fees and origination expenses; $5.9 million of accounts payable, including $1.1 million for Enteris’s internal pipeline projects; payroll and benefits expense of $6.3 million and $0.1 million of credit facility interest and other expenses. 24 Our ability to generate cash in the future depends primarily upon our success in implementing our Finance Receivables business model of generating income by providing capital to a broad range of life science companies, institutions and inventors, as well as the success of our Pharmaceutical Development segment. We generate income primarily from four sources: 1. Primarily owning or financing through debt investments, royalties generated by the sales of life science products and related intellectual property; 2. Receiving interest and other income by advancing capital in the form of secured debt to companies in the life science sector; 3. Pharmaceutical development, manufacturing, and licensing activities utilizing the Peptelligence® platform; and 4. To a lesser extent, realizing capital appreciation from equity-related investments in the life science sector. As of June 30, 2022, our finance receivables portfolio contains $174.9 million of finance receivables, $0.6 million of marketable investments, and $3.5 million related to our cost method investment. In the aggregate, we expect these assets to generate positive cash flows in 2022. In addition, the majority of our finance receivables portfolio are debt instruments that carry floating interest rates with a LIBOR-based interest rate floor. Changes in interest rates, including LIBOR rates, may affect the interest income for debt instruments with floating rates. We believe we are well positioned to benefit should market interest rates rise in the future. We expect the Pharmaceutical Development segment to generate positive cash flow above its expenses from proceeds received under its license agreements and customer relationships; however, the timing of the receipt of payments under the license agreements is uncertain and dependent upon the success of our technology licensees’ pharmaceutical development candidates. Though we expect in the aggregate that the Company will generate positive cash flow in excess of our expenses, given the abrupt decline in global economic activity, and the uncertain recovery from such decline, we cannot predict this with certainty. We entered into a $20.0 million revolving credit facility in June 2018. The credit facility was amended on September 27, 2021 to extend the termination date to September 30, 2022 and to increase the credit facility commitment to $22.0 million. We continue to explore options to either extend our current credit facility or obtain a new credit facility. As of June 30, 2022, $22.0 million was available for borrowing under the credit facility. Off-Balance Sheet Arrangements In the normal course of operations, we engage in a variety of financial transactions that, in accordance with GAAP, are not recorded in our consolidated financial statements. These transactions involve, to varying degrees, elements of credit, interest rate, and liquidity risk. Such transactions are used primarily to manage partner companies’ requests for funding and take the form of loan commitments and lines of credit. The contractual amounts of commitments to extend credit represent the amounts of potential accounting loss should the contract be fully drawn upon, the partner company defaults, and the value of any existing collateral becomes worthless. We use the same credit policies in making commitments and conditional obligations as we do for on-balance sheet instruments. Please refer to Item 1. Financial Statements, Note 6 of the notes to the unaudited condensed consolidated financial statements. 25 ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. During the six months ended June 30, 2022, our cash and cash equivalents were deposited in accounts at well capitalized financial institutions. The fair value of our cash and cash equivalents at June 30, 2022 approximated its carrying value. Investment and Interest Rate Risk We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flow. As we seek to provide capital to a broad range of life science companies, institutions and investors with the majority of our finance receivables portfolio paying interest based on floating interest rates with a LIBOR floor, our net investment income is dependent, in part, upon the difference between the rate at which we earn on our cash and cash equivalents and the rate at which we lend those funds to third parties. As a result, we are subject to risks relating to changes in market interest rates. We may use interest rate risk management techniques in an effort to limit our exposure to interest rate fluctuations by providing capital at variable interest rates. We do not currently engage in any interest rate hedging activities. We constantly monitor our portfolio and position our portfolio to respond appropriately to a reduction in credit rating of any of our investments. We have entered into a revolving credit facility. As we borrow funds to make additional investments, our income will depend, in part, upon the difference between the rate at which we borrow funds and the rate at which we invest those funds. As a result, we are subject to risks relating to changes in market interest rates. In periods of rising interest rates when we have debt outstanding, our cost of funds would increase, which could reduce our income, especially to the extent we continue to hold fixed rate investments. We generally seek to mitigate this risk by pricing our debt investments with floating interest rates to maintain the spread of our portfolio over the cost of leverage. If deemed prudent, we may use interest rate risk management techniques in an effort to minimize our exposure to interest rate fluctuations, which we have not done. Adverse developments resulting from changes in interest rates or hedging transactions could have a materially adverse effect on our business, financial condition and results of operations. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our investment income, net of borrowing expenses. Inflation We do not believe that inflation has had a significant impact on our revenues or operations. ITEM 4. CONTROLS AND PROCEDURES. Evaluation of Disclosure Controls and Procedures Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. In connection with the preparation of this report, our management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. Changes in Internal Control over Financial Reporting There have been no changes during the six months ended June 30, 2022 in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 26 PART II. OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS We are involved in, or have been involved in, arbitrations or various other legal proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these claims and other proceedings. The ultimate outcome of any litigation is uncertain, and either unfavorable or favorable outcomes could have a material negative impact on our results of operations, balance sheets and cash flows due to defense costs, and divert management resources. Currently, we are not involved in any arbitration and/or other legal proceeding that we expect to have a material effect on our business, financial condition, results of operations and cash flows. ITEM 1A. RISK FACTORS Information regarding the Company’s risk factors appears in “Part I. – Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 25, 2022. There are no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. None. ITEM 3. DEFAULTS UPON SENIOR SECURITIES. None. ITEM 4. MINE SAFETY DISCLOSURES. Not Applicable. ITEM 5. OTHER INFORMATION. None. 27 ITEM 6. EXHIBITS Number Exhibit Description Filing Filed Form Exhibit Date Herewith 31.01 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 31.02 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 32.01 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* X 32.02 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* X 101.INS+ XBRL Instance X 101.SCH+ XBRL Taxonomy Extension Schema X 101.CAL+ XBRL Taxonomy Extension Calculation X 101.DEF+ XBRL Taxonomy Extension Definition X 101.LAB+ XBRL Taxonomy Extension Labels X 101.PRE+ XBRL Taxonomy Extension Presentation X * These certifications accompany this Quarterly Report on Form 10-Q. They are not deemed “filed” with the Securities and Exchange Commission and are not to be incorporated by reference in any filing of SWK Holdings Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. + XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections. 28 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on August 10, 2022. SWK Holdings Corporation By: /s/ Winston L. Black Winston L. Black Chief Executive Officer (Principal Executive Officer) By: /s/ Charles M. Jacobson Charles M. Jacobson Chief Financial Officer (Principal Financial Officer) 29